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ABSTRACT: Many proteins of widely diﬀering functionality
and structure are capable of binding heparin and heparan
sulfate. Since crystallizing protein−heparin complexes for
structure determination is generally diﬃcult, computational
docking can be a useful approach for understanding speciﬁc
interactions. Previous studies used programs originally
developed for docking small molecules to well-deﬁned pockets,
rather than for docking polysaccharides to highly charged
shallow crevices that usually bind heparin. We have extended
the program PIPER and the automated protein−protein
docking server ClusPro to heparin docking. Using a molecular mechanics energy function for scoring and the fast Fourier
transform correlation approach, the method generates and evaluates close to a billion poses of a heparin tetrasaccharide probe.
The docked structures are clustered using pairwise root-mean-square deviations as the distance measure. It was shown that
clustering of heparin molecules close to each other but having diﬀerent orientations and selecting the clusters with the highest
protein−ligand contacts reliably predicts the heparin binding site. In addition, the centers of the ﬁve most populated clusters
include structures close to the native orientation of the heparin. These structures can provide starting points for further
reﬁnement by methods that account for ﬂexibility such as molecular dynamics. The heparin docking method is available as an
advanced option of the ClusPro server at http://cluspro.bu.edu/.
■ INTRODUCTION
Glycosaminoglycans (GAGs) are a diverse group of poly-
saccharides that participate in many biological processes
through the regulation of their protein partners.1−4 They are
produced by almost every cell type and are most frequently
found in the extracellular space and on cell surfaces where they
play important roles in mediating cell−extracellular matrix
interactions and cell−cell communication and in regulating
extracellular matrix structure and function.5−8 Heparan sulfate
(HS) represents a structurally varied family of GAGs. HS is a
polysaccharide of disaccharide units of alternating hexuronic
acid and D-glucosamine. Variations in disaccharide sulfation and
hexuronic acid structure are responsible for the diﬀerences
between and even within HS chains.1,3,9,10 Heparin, a particular
member of the HS family, consists of highly sulfated
disaccharides, and is frequently used as a model compound in
experimental and theoretical studies of protein−HS inter-
actions.11 Heparin is very important on its own right, and has
long been known for its capability as an anticoagulant, which
has been used in humans for almost one hundred years.8 The
mechanism of heparin action involves catalyzing the
inactivation of thrombin by antithrombin III by causing a
conformational change in antithrombin III.1,4 The ability of
heparin to bind to proteins involved in regulating other cell
processes such as cell proliferation suggests other medically
relevant interactions.3 Indeed, over the past two decades a
growing number of biological activities have been discovered to
be regulated by the interaction of heparin/HS with proteins
that play major roles in cancer, wound healing, infectious
diseases, and inﬂammatory processes. Thus, it is not surprising
that a 2002 review on heparin-protein interactions has been
cited over 1000 times.8
Given the importance of interactions between heparin/HS
and a very large variety of proteins, considerable eﬀort has been
invested in the identiﬁcation of protein regions that form such
interactions. Structures have been determined by X-ray
crystallography for a number of important protein−heparin/
HS complexes, including complexes of antithrombin III,
annexin V, and ﬁbroblast growth factors.2,12 However, the
crystallization of protein−heparin/HS complexes is challenging,
primarily due to inhomogeneity of GAG fragments and the
nature of ionic interactions that may allow for multiple binding
orientations.13 Because of these problems, X-ray structures are
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available only for a small fraction of proteins that are known to
interact with heparin/HS, and computational methods have
been frequently used for predicting the structures of speciﬁc
complexes. Early attempts were made to identify sequence
determinants required for binding, and although some
consensus sequences have been found, they are neither
necessary nor suﬃcient.14 A minimum requirement that
appears to be common to all heparin binding sites is the
concentration of basic residues in a particular area of the
protein surface (not necessarily close to each other in
sequence), oriented in a geometry that matches the pattern
of sulfate groups along the heparin/HS chain.11
The combination of the charged residues and the require-
ments of a geometry that can accommodate an elongated
heparin/HS molecule is expected to facilitate the identiﬁcation
of heparin binding sites and orientations using docking
methods, and a large number of such calculations have been
described in the literature. In most cases docking has been
predictively applied to speciﬁc proteins without much
validation, although in some cases the results were qualitatively
conﬁrmed by NMR titration or site-directed mutagenesis
experiments.11,15−22 The number of proper method validation
studies, involving known protein−heparin/HS structures as a
test set, appears to be relatively limited. In an early but still very
inﬂuential study,23 Bitomsky and Wade docked mono- and
disaccharide probes using a number of programs, namely
GRID,24 AutoDock,25 and DOCK.26 The test set included
three proteins: two structures taken from complexes of heparin
with ﬁbroblast growth factors, and the third the unbound
structure of antithrombin III. Searches were performed both
globally, i.e, considering the entire protein surface, and locally,
restricting considerations to a box around the known heparin
binding site. For each probe, results were given in terms of
“interaction probabilities”, deﬁned as the normalized number of
contacts between each residue and a set of low energy probe
poses. While this measure is less informative than RMSD (root-
mean-square deviation) from the native state used in most
traditional docking tests, the relatively high interaction
probabilities obtained for binding site residues indicate that
the methods were able to correctly localize the heparin binding
sites. However, it was also apparent that probes had comparably
low energies in several diﬀerent orientations. Rigid body
docking of hexasaccharides was also performed. It was observed
that in all docking runs, the crystal structure did not represent
the most favorable conformation with respect to the force ﬁelds
of the docking programs. These results were conﬁrmed by
more recent validation studies. Forster and Mulloy11 used
Autodock to dock an NMR structure of heparin to separately
crystallized structures of the three proteins considered by
Bitomsky and Wade.23 While the methodology used by Forster
and Mulloy11 appears to be fairly rigorous, they did not present
results beyond qualitative statements. More detailed results
were given by Samsonov et al.,27 who analyzed how solvent
inclusion aﬀects the results obtained by a number of docking
programs. Although the main result of the paper was that
inclusion of solvent improves results and that docking generally
yields near-native structures, it was also reported that, on
average, there were only 1.8 to 4.5 correct poses among the top
10 lowest energy structures. It was also shown that, in terms of
the energy, the average rank of the best (lowest RMSD) pose
was between 11 and 33, depending on the target protein.27
Thus, there seems to be an agreement in the literature that
docking generates near-native conformations, but selecting
them among the ones generated is still a problem.
Essentially all methods used in the above studies have been
developed for docking small molecules (with a few rotatable
bonds) to traditional drug target proteins with well-deﬁned
binding pockets. In addition, the methods generally assume that
the approximate location of the binding pocket is known, and
hence restrict the search to a box around the putative binding
site. In contrast, heparin/HS is substantially larger than the
small ligands considered as potential drugs, and it also has more
rotatable bonds. In addition, heparin/HS generally binds to
shallow solvent exposed crevices or even slightly protruding
regions on the protein surface rather than in deep pockets.
Although the binding region must be highly charged, a number
of sites on a protein may satisfy this condition, each allowing
for several orientations of the ligand. Thus, it is not clear
whether the small molecule docking methods oﬀer the best
tools for heparin/HS docking, and whether these methods can
predict position and orientations with an accuracy that is useful
in applications.
We have encountered the problem of heparin docking
problem as a participant in the CAPRI (Critical Assessment of
PRotein Interactions) worldwide protein docking experiment.
While the CAPRI targets are generally protein−protein
complexes, Target 57 in Round 27 of the experiment required
docking a six-sugar heparin to the unbound structure of
fragment 423−700 of the protein BT4661, a polysaccharide
binding protein from the Bacteroides thetaiotaomicron heparin
utilization locus. The predictor groups in CAPRI were given the
atomic coordinates of the protein and a generic heparin
conformation, and were expected to model the complex as
accurately as possible. The BT4661-heparin complex is now
deposited in the Protein Data Bank (PDB ID 4AK2), but at the
time of the CAPRI assignment no information was available on
the location of heparin binding, and the ligand-free structure of
the protein is still unpublished. Since the 423−700 fragment of
the protein BT4661 has two domains with a deep crevice
between the domains, and many positive charges on the
surface, locating the most likely binding pose with any
conﬁdence was far from trivial. We tried several approaches
described in previous papers on heparin docking. First we
mapped the protein using FTMap, a program developed for the
identiﬁcation and characterization of ligand binding sites,28
which can be considered as a substantially improved version of
the GRID program.29 FTMap found several pockets that could
favorably accommodate small ligands, but were not very likely
to bind an elongated heparin molecule. Next, as in a number of
previous studies, we docked mono and disaccharide fragments
of heparin using Autodock, but the program returned too many
potential binding sites, leaving us with a high level of
uncertainty. This results has shown that using existing program
is far from simple when there is no information on the site, as
in the case of CAPRI targets.
After experimenting with FTMap and Autodock, we decided
to use the docking program PIPER,30 also implemented in our
heavily used automated docking server ClusPro.31,32 ClusPro
was the ﬁrst automated protein−protein server, and based on
the results of the last three CAPRI evaluation meetings, it
consistently has been the most accurate among such
servers.33−35 The server is heavily used: by December 2013
we registered over 8600 unique user IPs, and the server
completed almost 57 000 docking jobs, currently about 2000
per month. Models built by ClusPro have been reported in over
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250 publications. Since PIPER and ClusPro were developed for
protein−protein docking, neither had the parameters needed
for heparin docking, and thus had to be appropriately
expanded. This approach was fairly successful, at least when
compared to the results of the other 30 groups that participated
in CAPRI and submitted predictions for Target 57. Based on
the evaluator’s report,35 we obtained two medium quality
models, with ligand RMSD (after superimposing the receptors)
below 5 Å and interface RMSD (for residues within 10 Å of the
interface) around 2 Å. There were two other groups that
achieved comparable accuracy, but our model predicted the
highest fraction of native contacts.35
On the basis of our successful prediction at CAPRI we
decided to establish a general method and to add heparin
docking as an advanced option to the ClusPro server. The goal
of this paper is to describe this new development and the
resulting capabilities. As shown by the CAPRI results, ClusPro
is competitive with other approaches. However, the method
also has clear limitations, and can be used only as the ﬁrst step
toward determining heparin−protein interactions. In fact,
ClusPro performs rigid body docking of a generic tetrasac-
charide heparin probe, allowing for some ﬂexibility in a
reﬁnement step. In this step we perform oﬀ-grid energy
minimization during which all atoms of the heparin chain and
all protein side chain atoms within 5 Å of the heparin molecule
are allowed to move freely. Although we explored the
possibility of pregenerating and docking a number of
conformers of the heparin tetramer, we decided to perform
only local minimization for three reasons. First, the backbone in
short heparin fragments is relatively conserved. Second,
although the orientation of the sulfate groups is highly variable,
due to the strong ionic interactions these are heavily aﬀected by
the positions of charges on the protein, and hence
precalculating conformations generally does not improve the
accuracy of predicting the binding pose. Third, generating and
docking possible conformers would increase our algorithm’s
runtime to unreasonable lengths, making the calculations too
expensive for a web-based server. Therefore, our main objective
is to predict the location of the heparin binding site, deﬁned in
terms of amino acid residues that are in contact with the ligand,
and possibly some of the most likely orientations of the heparin
chain, and we do not attempt to predict detailed interactions at
the atom−atom level. As will be shown, the binding sites
identiﬁed by the server are reliable. In addition, some of the top
poses are generally not very far from the native orientation of
the heparin. Thus, we hope that adding heparin docking to
ClusPro will be useful to the research community as the ﬁrst
step toward constructing more accurate interaction models.
The models generated by ClusPro can be conﬁrmed or rejected
using data from low resolution experiments, and can be reﬁned
by molecular dynamics (MD) or Monte Carlo simulations that
use the speciﬁc heparin/HS molecule rather than the generic
tetrasaccharide, allow for ﬂexibility, and may explicitly account
for the eﬀects of the solvent.
■ METHODS
ClusPro Server. Heparin docking was added as an advanced
option to our protein−protein docking server ClusPro. The
server has been in operation since 2004,31 and it was
substantially upgraded to Version 2.0 in 2007.36 The ﬁrst
step of the current version is a global rigid body docking using
PIPER, which as based on the fast Fourier transform (FFT)
correlation approach.30 In PIPER the smaller molecule (i.e., in
our current application the heparin), is considered the ligand,
which is moved about the protein receptor on a 3D grid with
spacing 1.0 Å, using 70 000 rotations at each grid point. For a
protein of average size this means close to a billion function
evaluations. The advantage of the FFT approach is that a
scoring function, written as a sum of correlation functions, can
be evaluated extremely eﬃciently, and thus sampling the very
large number of conformations is computationally feasible.30
For heparin docking, the interaction energy type scoring
function is calculated using three terms: van der Waals
attractive, van der Waals repulsive, and electrostatic energy.
Weights for each of these terms were selected to maximize
accuracy in a test set of heparin binding proteins (see Results).
As will be described, in the heparin docking mode we perform
sampling using two diﬀerent weight sets, and from each sample
we retain the 900 lowest energy structures.
The second step performed by ClusPro is clustering the
retained structures using pairwise RMSD as the distance
measure.37 The biophysical meaning of clustering is isolating
highly populated low-energy basins of the energy landscape.38
Several studies, including ours,31 have demonstrated that
clustering algorithms generally perform better for isolating
near native structures as compared with selecting low-energy
conformations, if used in conjunction with exhaustive energy-
based sampling such as in PIPER. The clustering of the 1800
poses starts with the lowest energy pose and grouping all poses
within 9 Å. From the remaining poses not already grouped, the
lowest energy pose is selected and the process repeats until no
poses remain. Clusters of 10 or fewer poses are not considered.
The clusters are then ranked by population and represented by
the lowest energy structure. Unless requested otherwise by the
user, ClusPro returns the representatives of the 10 largest
clusters along with cluster populations. Finally, the structures
are reﬁned by minimizing the Charmm energy of the
complexes. All heparin atoms and all side chain atoms within
5 Å of the heparin are allowed oﬀ-grid ﬂexibility during
minimization, then the protein atoms are reset and a ﬁnal
minimization resolves collisions. While the minimization
generally removes potential steric clashes, it does not
substantially change the conformation of the complexes, and
thus the RMSD of our ClusPro submissions from the native
complexes is fully determined by the rigid-body docking and
clustering steps.38
Test Set Selection. To select a test set of heparin-binding
proteins, the RCSB Protein Data Bank (www.pdb.org)39 was
searched for structures containing both 2-O-sulfo-alpha-L-
idopyranuronic acid and N,O6-disulfo-glucosamine; the two
most common sugars making up heparin chains. Several
structures contained a single 4-deoxy-2-O-sulfo-alpha-L-threo-
hex-4-enopyranuronic acid in place of 2-O-sulfo-alpha-L-
idopyranuronic acid when that sugar was the terminal sugar
in the heparin chain. From these structures, we selected only
proteins for which an unbound form with sequence similarity of
95% or better was also available. Additional cases were removed
from consideration for containing essential ions in the heparin
binding site, for structures whose heparin coordinates
contained errors that proved insurmountable in our preparation
steps, and for multiple conformations of the same protein
target. These selection criteria resulted in a small test set of ﬁve
proteins listed in Table 1.
Heparin Parametrization. The heparin molecule was
extracted from each bound structure and parametrized for use
in the ClusPro program. The molecules were given unique
Journal of Chemical Information and Modeling Article
dx.doi.org/10.1021/ci500115j | J. Chem. Inf. Model. 2014, 54, 2068−20782070
atom naming and each atom was assigned a value for partial
charge, radius, mass, and hydrogen bond acceptor/donor status.
Each atom was also assigned a mol2 atom type and bond
lengths, bond angles, and bond torsions were calculated for
each unique bond. The quantum chemistry system GAMESS49
was used to compute Austin Model 1 (AM1) atomic charges;
the information was then piped through molecule manipulation
scripts (http://charles.karney.info/b2d-scripts/) using the
molecular mechanics suite ANTECHAMBER50 to perform
bond charge corrections (BCCs) and to generate the ﬁnal
AM1-BCC atomic charges. ANTECHAMBER generates
GAFF-based51 topology ﬁles and parameter ﬁles in the
Charmm format.52 GAFF is a complete force ﬁeld, i.e.,
parameters are either available for all atom types or can be
computed using empirical rules.51 The molecular parameters
were then copied to the ClusPro server to allow for each
heparin molecule to be used as a ligand in interaction
predictions.
Selecting a Quality Measure. Since we will cross-dock
heparin/HS ligands that may have diﬀerent chemical structures,
we need a quality measure that allows for superimposing such
molecules. We will therefore use RMSD deﬁned in terms of a
subset of atoms from each heparin chain. Each subset contains
a single carbon atom from each sugar residue. This carbon
atom is a member of the six-member ring in each sugar bonded
to the oxygen in the ring as well as a second oxygen not in the
ring. It is typically named C1 in all heparin sugars and is the
only carbon in the ring bound to two unique oxygen atoms. In
addition, this atom is along the heparin backbone if we consider
the backbone to be a string that passes through the connectors
between sugar residues and around which the residues may
rotate, and hence the RMSD deﬁned in terms of these atoms
will describe the overall position and orientation of the docked
heparin molecule relative to the native ligand. We note that the
RMSD measure involving a single carbon atom from each
heparin subunit is similar to a backbone RMSD frequently used
for describing the accuracy of results in protein−protein
docking, and allows for heparin chains of varying length to be
compared using a method similar to a sliding window. It is also
more forgiving to diﬀerences in heparin conformation while
remaining a valid indicator of heparin position and orientation.
Binding Site Prediction. Using the representative poses
from ClusPro, an additional round of clustering was added to
form binding sites. In this step heparin poses are clustered by
proximity as before, but this time each pose is represented as a
single point at its center of mass rather than the positions of all
C1 carbon atoms. Clusters that fail to meet a minimum
population threshold are not considered. Another diﬀerence is
that the clusters are ranked by the highest number of protein−
heparin contacts per contacting protein atoms rather than by
cluster population. Thus, the cluster making most contacts with
the protein at any single atom is ranked highest.
■ RESULTS
Selecting Scoring Function Coeﬃcients. In a standard
run of the ClusPro server, a ligand (usually the smaller
molecule) is systematically positioned about a receptor and the
receptor−ligand interaction energy is calculated by several
parameters in our rigid docking program PIPER. The best
poses are then clustered to select the most likely positions and
orientations of the ligand to the receptor. This functional
approach was originally optimized for protein−protein docking,
including minor adjustments for speciﬁc interactions such as for
enzyme−inhibitor or antibody−antigen pairs. Our objective
here is to optimize ClusPro for predicting protein−heparin
interactions, involving the selection of scoring function
coeﬃcients and the selection of an appropriate heparin probe.
The molecular mechanics scoring function of PIPER we use
for heparin docking has the general form E = wattrEattr + wrepErep
+ welecEelec, where Eattr and Erep denote the attractive and
repulsive contributions to the van der Waals interaction energy
and Eelec is an electrostatic energy term.
30 The coeﬃcients wattr,
wrep, and welec specify the weights of the corresponding terms,
and are optimally selected for diﬀerent types of docking
problems.38 In order to select appropriate weight coeﬃcients
for heparin docking we considered the test set of heparin-
bound protein structures listed in Table 1. The heparin
structure was extracted from each complex, parametrized,
loaded into ClusPro, and docked to the unbound (separately
crystallized) protein structure. We attempted, but were unable,
to discover a single set of weights capable of successfully ﬁnding
the binding site on all test systems, so an approach that takes
two weight sets and concatenates them prior to clustering was
developed. In both sets wrep = 0.40 and welec = 300, and only the
weights of the attractive van der Waals contributions diﬀer: wattr
= −0.40 in one set and wattr = −0.10 in the other, the latter
generating complexes with weaker shape complementarity.
Since the FFT method evaluates the diﬀerent energy terms
separately, generating results using two diﬀerent sets of weights
does not increase the computing time. For each set, we retain
the 900 lowest energy docked structures, and the resulting 1800
structures are clustered as described previously.
Selection of a Heparin Probe. In applying CluPro to
heparin docking, the next step was to ﬁnd a heparin molecule
capable of representing all heparin chains in any protein−
heparin interaction. Each of the heparin ligands was then
docked to all ﬁve unbound protein structures in the test set.
The results of this all-against-all comparison of the structures
show that just one heparin molecule, from PDB structure
3QMK, is capable of predicting the bound pose of the ﬁve test
cases within 10 Å. The results of docking this heparin structure
against the ﬁve targets in the test set are shown in Table 2.
Docking Results for the Test Set. As shown in Table 2,
docking of the selected heparin probe, the binding site for
heparin can be predicted by the consensus of calculated heparin
poses. In addition, ClusPro is capable of returning a high
ranking, low RMSD result for heparin binding. These best
poses are shown in the ﬁrst column of Figure 1 for each test
system. In these ﬁgures, the unbound protein is shown with the
actual heparin pose (obtained by aligning the bound protein to
the unbound protein) in green sticks, while the best predicted
pose is shown in thin, cyan sticks. For each system, the
Table 1. List of Heparin Bound Protein Structures and their
Unbound Formsa
protein
unbound
PDB
bound
PDB
heparin
length
human 3-O-Sulfotransferase-3 1T8T40 1T8U40 2
E2 domain of amyloid precursor-like
protein 1
3Q7L41 3QMK42 2
NK1 fragment of human hepatocyte
growth factor/scatter factor (HGF/SF)
1NK143 1GMN44 2.5
plasma serine protease inhibitor 1LQ845 3DY046 2.5
basic ﬁbroblast growth factor 1BFG47 1BFC48 3
aLength of heparin chain present in bound structures given in terms of
disaccharides.
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predicted pose forms more atom−atom interactions than the
actual heparin pose. This is a consequence of the ClusPro
algorithm’s energy calculation, which results in several
predictions in the correct relative position but closer to the
target protein. However, in the case of 1LQ8 the actual heparin
pose bridges a gap between two projecting amino acid residues
(Arg26 and Asn230), while the predicted pose runs
perpendicular down the valley between those residues, entirely
beneath the actual heparin bridge.
As shown in Table 2, the ﬁve largest clusters generally
include heparin poses that have the right orientation (with less
than 10 Å RMSD from the native), but not necessarily the best
rank. An atom−atom contact map is provided to show useful
features even in such cases if no a priori information is available.
For this map, each interaction of 4 Å or less from all returned
representative poses is counted, and each protein atom is
colored by its number of contacts. The second column in
Figure 1 shows the contact map for the ﬁve proteins in the test
set. Clearly shown along with the correct pose (obtained by
aligning the bound protein to the unbound protein) are the
contact maps. In each case, the hottest (reddest) area of the
contact map correctly predicts the location of the bound
heparin. Whiter areas have fewer contacts while dark areas have
none. Only in the case of 1NK1 was there a secondary contact
site (not shown), though it was clearly less important than the
primary contact site shown here.
Analysis of Predicted Contacts. To observe the accuracy
of predicting heparin binding sites on unbound protein
structures, the contacts per protein residue were charted.
These charts are given below in Figure 2.
For these charts, the number of contacts made (atom−atom
distance ≤ 4.0 Å; y-axis) were counted per residue of the
protein (x-axis). Counts of the contacts in the actual bound
case (orange) were normalized to the same scale as the
predicted unbound case (blue). These graphs show a general
matching trend that any contacting residues are correctly
predicted to have atom−atom contacts with the heparin chain.
They also show many cases where a residue is predicted to
form contacts with the heparin, though no true contacts are
formed. In fact, in some cases ClusPro, which tends to optimize
contacts, generates models that have better shape complemen-
tarity than the real protein−heparin complex. This problem will
be discussed further in the paper.
Applications to Further Proteins. The extended ClusPro
server was further tested against additional proteins that did not
meet our original criteria for inclusion into the test set. In one
such system, Annexin V, calcium ions present in the binding
site create a favorable pocket for binding that would not
otherwise exist.53 These ions were also found in a PDB entry of
the unbound protein.54 This unbound conformation with the
included ions was run with the new heparin docking approach.
The best result, shown in Figure 3, had an RMSD of 6.66 Å and
was ranked second.
We also docked heparin to segment FN12−FN14 of human
ﬁbronectin for which the structure of the bound conformation
was not available, but one heparin binding site and one
potential heparin binding site were described in the literature.55
Results for this ﬁbronectin model are shown in Figure 4 (PDB
ID 1FNH). To run this protein model, the structure was
divided into separate domains FN13 and FN14 as described.55
The FN13 domain contains the heparin binding site conﬁrmed
by mutation studies, and consisting of residues R98, R99, R101,
R115, and K117 (residue numbering is based on the X-ray
structure of the FN12−FN14 fragment).55 R146 may also be
part of the binding site, but it is slightly removed from the other
residues, in line with the mutagenesis data where change of
R146 to S reduces heparin binding only 3-fold, whereas
mutation of any of the other ﬁve residues reduces it at least 10-
fold.55 For this domain, the correct binding site was the only
Table 2. List of Bound and Unbound Protein Conformations
Used for Docking Prediction as well as Rank and RMSD of
Best Prediction and the Rank of the Binding Site
bound PDB
ID
unbound
PDB ID chain
best probe
rank
RMSD
(Å)
binding site
rank
1T8U 1T8T B 5th 7.995 1st
3QMK 3Q7L A 5th 5.961 1st
1GMN 1NK1 A 3rd 8.959 1st
3DY0 1LQ8 A 1st 7.510 1st
1BFC 1BFG A 2nd 3.499 1st
Figure 1. Best results and contact maps of the ﬁve test systems. (left)
Unbound protein shown with the actual heparin pose (in green sticks).
The best predicted pose is shown in thin, cyan sticks. (right) Contact
maps. Red (hot) areas have large number of contacts with the docked
heparin poses, white areas have fewer, and dark areas have none.
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ClusPro predicted binding site and it accurately centers on the
implicated bound residues. The top three clusters predict an
orientation very similar to the cluster ranked 1 (shown in
magenta in Figure 4), and they all interact with the side chains
R98 and R99, considered key to heparin binding. The FN14
domain contains a predicted binding site with several positively
charged residues.55 These residues are more scattered than the
heparin binding residues on FN13. Indeed, peptides from
FN14 spanning residues 204−210, 217−235, and 257−271
have been implicated independently, and thus there is a level of
uncertainty concerning the binding site on FN14. Accordingly,
ClusPro predicts more diverse heparin poses than for FN13,
and based on cluster sizes the binding to FN14 is substantially
weaker. In fact, when docking to the entire FN12−FN14
segment, the top 7 clusters are at the heparin binding site of
FN13, and only cluster 8 is located on FN14. Mapping of the
latter segment separately, the top three poses are found at the
site represented by poses 1 and 2 in Figure 4A. Poses 4 and 5
(not shown) are shifted as the continuation of pose 1 (cyan)
Figure 2. Atom−atom contacts between heparin chains and protein residues. Predicted heparin chains are shown in blue; actual chains (normalized)
are in orange. The x-axis is protein residue sorted by residue number where only residues that had at least one atom−atom contact are included for
clarity.
Figure 3. Results for Annexin V (PDB IDs 1G5N for the bound
structure, 2IE7 for the unbound). Calcium ions are shown as green
spheres. (A) Best predicted structure shown as thin cyan sticks. The
native binding mode is shown in green. Notice that as in many other
cases, the predicted structure is closer to the surface than the native
one. (B) Heat map based on heparin docking. Red (hot) areas have
large number of contacts with the docked heparin poses, white areas
have fewer, and dark areas have none.
Figure 4. Results for human ﬁbronectin (Unbound PDB 1FNH).
Subunit FN13 is on the left and FN14 is on the right. (A) Predicted
heparin binding residues are shown in blue. For FN13 we show the
predicted heparin poses ranked 1 (magenta) and 8 (green). For FN14
we show the poses ranked 1 (cyan) and 2 (yellow). (B) Same as A
with the protein shown as a cartoon. The R and K residues of the
heparin binding site are shown as sticks. Only the top ranked heparin
poses are shown.
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toward the intersegment region on the back of the protein.
Based on these ﬁve clusters, we predict that the residues most
likely involved in heparin binding are K216, R230, R232, and
K261. While R225 (shown on the right from the other binding
residues) seems to be separated, its long side chain can also
interact with the bound heparin. In addition, R207, R209, and
K257 are oriented toward the intersegment region, and most
likely can interact with longer heparin chains. Based on the
repeated appearance of poses similar to the top ranked ones
(magenta and cyan in Figure 4) among the docked structures,
we consider it likely that such orientations occur.
It is generally assumed that a heparin chain of 12−16
saccharide units bridges the two FN13 and FN14 segments.55
We show the poses ranked 8 for FN13 (green) and ranked 2
for FN14 (yellow) in Figure 4A, because their orientation
extends the top ranked poses toward the other FN segment.
Indeed, the two poses have the right directionality and distance
(19.2 Å) to be connected by adding a tetrasaccharide unit
bridging the intersegment region, without any major interaction
with the protein. The resulting model is more curved than a
recent model obtained by rigid docking of a standard heparin
dodecasaccharide to the FN12−FN14 structure, where some
interactions also occur with the FN12 segment.21 In contrast,
predicting only the tetrasaccharides binding to FN13 and
FN14, our model does not reach FN12. Most of our top poses
on FN13 are placed between the side chains of R98, R99, R101,
and R115. According to an NMR study, only these residues are
required for the binding of an octasaccharide to the FN13−
FN14 units.55 Of course, the predicted importance of the four
residues does not prove that the model is correct, and further
experimental studies, particularly exploring the heparin binding
residues on FN14, are required for a better understanding of
the binding mode.
Comparison to Other Computational Approaches.
The method presented in this paper has been developed from
our protein−protein docking program ClusPro speciﬁcally for
heparin docking. Thus, for comparisons we restrict consid-
erations to published heparin docking studies, as we have no
intention to apply this option to any other problem. Although
predictive heparin docking is performed in a substantial number
of papers, very few studies evaluate the algorithm on test
problems involving known protein−heparin structures. As
mentioned in the introduction, systematic evaluations can be
found in the papers by Bitomsky and Wade23 and Samsonov et
al.27 However, comparing their results to ours is far from
straightforward, since in each test problem both studies
considered the known structure of a protein−heparin complex,
separated the two molecules, and docked them back. Although
some of the methods allowed for heparin ﬂexibility, the protein
was always kept ﬁxed in its heparin-bound conformation.
Furthermore, Samsonov et al.27 restricted the search to a very
tight box centered on the true bound position of the ligand. In
contrast, our method has been developed to solve realistic
heparin docking problems, and thus in each test case we
consider the unbound (i.e., separately crystallized) protein and
the generic tetrasaccharide built into ClusPro, and perform a
global search over the entire protein surface without any
assumption on the location of the binding site. We were able to
ﬁnd unbound protein structures for most complexes considered
by Bitomsky and Wade23 and Samsonov et al.,27 and used these
structures in our calculations. Based on the known complex
structures we were able to determine that our method correctly
identiﬁed the binding site in all cases. However, since we solved
a very diﬀerent problem using much less information on the
targets, assessing the accuracy of docking in terms of RMSD
from the native complex structures does not provide a very
informative comparison to earlier results.
Bitomsky and Wade studied two test cases using known
heparin-bound structures, namely the complexes of ﬁbroblast
growth factor proteins bFGF (PDB ID 1BFC48) and aFGF
(PDB ID 2AXM56). In both cases the bound protein structures
served as the receptors. The heparins were ﬁrst docked as rigid
body chains, then a single disaccharide was used as a probe, and
lastly the ﬂexible sugar chains were docked to the proteins. The
initial rigid body approach was a simple test of the algorithms.
The disaccharide probe was used to identify the heparin biding
site. Finally, the ﬂexible docking performed a complete test of
these algorithms. Docking our generic tetrasaccharide to the
separately crystallized ﬁbroblast growth factor structures, we
were able to identify the correct binding sites in both cases. For
bFGF (unbound PDB ID 1BFG),47 our best pose was ranked
ﬁrst with an RMSD of 3.51 Å using the previously deﬁned
backbone RMSD measure. This result was similar to the one
obtained by Bitomsky and Wade,23 who docked the bound
heparin structure extracted from the complex to the heparin-
bound structure of bFGF, and reported 4.1 Å as the best
RMSD from the native complex, both using AutoDock and
DOCK. For aFGF (unbound PDB ID 3K1X57), our best pose
was ranked third with an RMSD of 6.56 Å. Again, Bitomsky and
Wade23 used the original bound heparin conformation as the
ligand, and docking to the heparin-bound structure of the
protein they were able to achieve their best result at 4.1 Å with
AutoDock and 14.2 Å with DOCK. In view of this broad range,
our result seems to be completely acceptable, particularly
considering that we globally dock to the unbound protein
structure.
Samsonov et al.27 examined ten proteins that were
cocrystallized with various glycoaminoglycans (GAGs) rather
than heparin, and hence were not selected for our original test
set. Of these ten systems, nine were found to have unbound
structures available (see Table 3). The authors docked the
minimized GAG structures to the bound protein structures
using a box around the bound ligand position, thus performing
Table 3. List of Bound and Unbound Protein Conformations
Used for Docking Prediction by Samsonov et al. as well as
Rank and RMSD of Best Prediction and the RMSD of the
Top Ranked Pose
bound
PDB ID
unbound
PDB ID
best
probe
rank
best probe
RMSD (Å)
top rank
RMSD (Å)
binding
site rank
1OJN58 1N7O58 5th 4.35 6.84 1st
1RWH59 1RWA59 2nd 4.32 9.71 1st
1G5N60 2IE754 2nd 6.66 8.60 1st
1T8U40 1T8T60 5th 8.00 8.36 1st
3E7J61 2FUQ62 7th 2.55 12.20 1st
2HYU63 2HYW63 9th 8.05 17.23 1st
2BRS64 1H8U65 12th 4.21 13.38 1st
1BFB48 1BFG47 2nd 3.50 8.54 1st
3IN966 3IMN66 4th 2.50 6.07 1sta
2nd 5.13 8.68 1sta
aSystem 3IN9/3IMN contained two GAG binding sites, both are
shown. The binding site for 3IN9 spanned the two bound
disaccharides, resulting in both bound poses in the top ranked binding
site.
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local rather than global docking. In contrast, we performed
global docking of the generic tetrasaccharide to unbound
proteins. As shown in Table 3, ClusPro ranked ﬁrst the correct
binding site in all cases, and for most proteins it also generated
poses with fairly low RMSD from the bound structure.
However, in some cases the best-ranked orientations had
substantially higher RMSD values. As we will further discuss,
this result emphasizes that lower ranked clusters generated by
ClusPro should also be considered for reﬁnement.
■ DISCUSSION
Heparin and other glycosaminoglycans are garnering attention
as important regulators of function of many proteins, as well as
potential drug molecules. Heparin has been used as an
anticoagulant for almost a century and its mechanism of action
suggests that many other uses may be possible.3,4 Since
crystallizing protein−heparin complexes for structure determi-
nation is generally diﬃcult, computational docking can be a
useful approach for understanding speciﬁc interactions. The
size of heparin chains has provided a challenge for methods
originally developed for docking small molecules such as
AutoDock or DOCK, as well as methods that speciﬁcally target
the prediction of protein−protein interactions such as our
PIPER program and the ClusPro server. Our representative
heparin probe is much larger than the small molecules handled
by AutoDock, but signiﬁcantly smaller than the typical protein
uploaded to ClusPro. This required new parameters adjusted
for molecules of this size. With appropriate updates we have
extended the capabilities of the ClusPro server to include
heparin molecules. To our knowledge, there does not already
exist an interaction prediction software speciﬁc to heparin chain
binding site prediction.
A single heparin tetrasaccharide was selected to serve as the
default representative for heparin docking using ClusPro, and
the approach has proven to be successful against all test targets
in predicting the heparin binding location. This observation is
in good agreement with previous reports. As noted by Mulloy
and Linhradt,12 a relatively short heparin is a well-behaved
ligand for rigid docking and the site on a protein surface where
heparin binds can be identiﬁed with good reliability. Indeed, the
conformation of heparin appears to be unusually well-deﬁned
compared with other polysaccharides: in both solution studies
of unbound heparin and crystal structures of complexes,
heparin is a ribbon-like molecule with sulfo groups arranged in
clusters along opposite sides of the polysaccharide chain.12
Forster and Mulloy used several heparin structures for docking,
but noted that in no case has the diﬀerence between the two
conformations given rise to substantially diﬀerent predictions.11
The number of rotatable bonds, 22 even in this short chain,
could generate over one billion conformations. These two facts
precluded using multiple conformations of the heparin chain.
However, it was also noted that the exact details of the
interactions with proteins cannot be accurately predicted by
docking calculations, whether or not ﬂexibility is taken into
account.12 Accordingly, our objective is the reliable identi-
ﬁcation of the heparin binding site and possibly determining
the most likely orientations of the tetrasaccharide. Using
ClusPro we generate and evaluate a very large number of
docked structures and determine a consensus binding area with
good reliability. As expected, the method does not provide a
simulation of the interaction or give any details of interactions
between speciﬁc atoms in either structure. However, we expect
that the results provide information for further exploration of
the interactions between the protein and the speciﬁc heparin/
HS molecule using more detailed simulation tools, primarily
molecular dynamics. In fact, without the initial docking and
clustering for the identiﬁcation of the binding site it may be
premature to focus on details.
Of the heparin chains examined, the selected tetrasaccharide
probe was the shortest. With the longer chains, it was typical to
see the tails peel away from the protein surface and move out
into space toward the position of the neighboring protein in the
crystal lattice. This caused heparin conformations with only half
of the chain bound, followed by an unusual bend away from the
protein surface. This was not seen in the shorter heparin
molecules that were bound to the protein surface for the entire
length of the chain. Therefore, we selected a heparin
tetrasaccharide probe without the bend for predicting the
binding site on proteins. In addition, this chain length is
representative of a majority of available heparin bound
structures in the Protein Data Bank, as longer structures are
not free of the artifacts just described. In view of this limitation
on the available structures, we do not generate three-
dimensional models of chains longer than four saccharide
units, as we have no basis for comparison.
In spite of correctly predicting the binding sites, we
encountered diﬃculties that required some attention. First,
several target proteins contained multiple chains and ClusPro
favored the crevices found in the region between chains. Our
solution was to run only a single chain at a time, though
masking the region between chains (an advanced ClusPro
option) would also have worked. Second, several structures
contained near identical chains, and ClusPro found the same
site on an identical chain, even if there was no heparin molecule
present there in the bound protein structure. This caused very
large RMSD values from the native complex. Lastly, on the
HGF target protein (PDB ID 1NK1), a second location
attracted many heparin poses and caused a predicted secondary
binding site. This secondary site, however, occurs between two
distinct protein domains and looked very similar to the
inaccurate results found between multiple protein chains. It
would be easy to exclude this fault by masking such a site or by
cutting the chains into distinct domains.
More generally, we already mentioned that ClusPro
frequently predicts heparin binding closer to the surface than
the one observed in X-ray structures. This is particularly
troubling for longer heparin chains because in many cases it is
assumed that some part of the chain does not directly interact
with the protein, but it is simply held in place by heparin
segments that do. The assumed bridging of the ﬁbronectin
segments FN13 and FN14 is an example. Indeed, it is
recognized that an important function of heparin/HS is to
mediate and regulate protein−protein interactions, and this
generally involves much longer heparin/HS molecules than the
tetrasaccharide we routinely dock. Thus, it appears that it would
be reasonable to modify the scoring function by further
reducing the van der Waals attraction term, or penalizing the
removal of solvent from charged residues, i.e., reducing direct
interactions with the protein. However, a scoring function with
such properties would not necessarily be able to place the short
(tetrameric) heparin fragments. Thus, the optimal scoring
function would depend on the length of the heparin chain. In
principle, this would not be a problem, because we could
optimize the interaction energy weight in a length-dependent
matter. The real problem is that, apart from a few very special
cases, there are no structures available for proteins with heparin
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chains longer than eight saccharide units, and thus we have no
data to parametrize and test the potential. Additional
complications arise when one considers that most HS chains
have considerably more structural variability than heparin, with
long stretches of un- and undersulfated regions that might be
involved in protein binding through mechanisms not captured
by our model.
In spite of the above limitations, we hope that the new
heparin binding site detection option in ClusPro will provide
preliminary assistance in many areas where heparin is a focus of
research. As shown, the server reliably identiﬁes the heparin
binding site, including the list of contact residues, on any
protein. In combination with other methods, both computa-
tional and experimental, ClusPro may ﬁll an imperative, though
seemingly absent, role providing users with accurate
information quickly and easily. The ClusPro server is freely
available for academic and governmental research at http://
cluspro.bu.edu/.
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